+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Iodine Metabolism in Chronic Renal Insufficiency

      , , ,


      S. Karger AG

      Thyroxine, Uremia, Iodine, Renal failure, Thyroid

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Iodine metabolism has been studied in 20 patients with advanced chronic renal insufficiency due to primary renal disease, and thyroxine turnover in another 5 similar patients. Comparatively to 18 controls, the uremic patients had a lower urinary iodine excretion, and a much lower renal iodide clearance, which, however, was not as much decreased as the creatinine clearance. The normal relation between the renal iodide and creatinine clearances was disturbed when the latter was 6.3 ml/min or lower, and in these cases the renal iodide clearance exceeded the corresponding creatinine value. The plasma inorganic iodine (PII) was increased because of the iodide retention to (mean ± SE) 0.84 ± 0.17 µg/100 ml, compared to 0.12 ± 0.01 in the controls. The thyroidal iodide clearance (Th. Cl.) rate was decreased (22.8 ± 4.44 ml/min vs. 36.7 ± 6.48), but in spite of this decrease, the absolute iodine uptake (AIU) by the thyroid, which is calculated as AIU = Th. Cl. X PII, was increased (7.1 ± 1.37 vs. 1.9 ± 0.30 µg/h). The serum protein-bound iodine was normal. The PII, Th. Cl. and AIU values and the relation among them in renal insufficiency were comparable to those observed after chronic administration of small amounts of iodine. The radiothyroxine studies suggested an increased space of distribution and so, despite a decreased fractional turnover rate, an increased metabolic clearance and degradation rate.

          Related collections

          Author and article information

          S. Karger AG
          27 November 2008
          : 9
          : 1
          : 55-65
          Athens University Department of Clinical Therapeutics and Thyroid Section, Alexandra Hospital, Athens
          180133 Nephron 1972;9:55–65
          © 1972 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11

          Cardiovascular Medicine, Nephrology

          Iodine, Thyroid, Renal failure, Uremia, Thyroxine


          Comment on this article